Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 11/20 | 0.42 |
| ▸ | GCGR | P47871 | 4/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | GIPR | P48546 | 1/20 | 0.35 |
| ▸ | STAT1 | P42224 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Beta-Alanine SCHEMBL6494757 | 0.81 | GCGR (0.51) | STAT3GCGRCETPEPHX1 | |
| SCHEMBL6494754 | 0.76 | GCGR (0.60) | STAT3GCGRGIPR | |
| SCHEMBL2652974 | 0.73 | GCGR (0.71) | STAT3GCGRGIPR | |
| SCHEMBL4095401 | 0.73 | GCGR (0.71) | STAT3GCGRGIPR | |
| SCHEMBL2653512 | 0.69 | GCGR (0.68) | STAT3GCGRGIPR | |
| SCHEMBL2654233 | 0.66 | GCGR (0.58) | STAT3GCGRGIPR | |
| SCHEMBL2665560 | 0.65 | GCGR (0.65) | STAT3GCGRGIPR | |
| SCHEMBL2665525 | 0.65 | GCGR (0.76) | GCGRGIPR | |
| SCHEMBL2655374 | 0.64 | GCGR (0.80) | GCGRGIPR | |
| SCHEMBL2652517 | 0.64 | GCGR (0.60) | STAT3GCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203108-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | STAT3 1079/4885GCGR 3/4885CETP 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.